Background: Type 1 insulin-like growth factor receptor (IGF-1R) mediates resistance to chemotherapy and targeted agents. This study assessed the safety, pharmacokinetics (PK), and tolerability of humanized IGF-1R antibody AVE1642 with other cancer treatments.
introduction Type 1 insulin-like growth factor receptor (IGF-1R) regulates cell cycle progression, cell survival, and invasion and, in preclinical studies, mediates resistance to chemotherapy and targeted biological agents [1] . Clinical trials testing IGF-1R antibodies with chemotherapy showed activity in nonsmall-cell lung cancer (NSCLC), prostate, and pancreatic cancer [2] [3] [4] [5] . However, a phase II study in colorectal cancer suggested antagonism between IGF-1R antibody and irinotecan [6] , and phase III figitumumab trials were discontinued after interim analysis indicated no benefit in unselected NSCLC patients [7] . To enable effective use of these new drugs, it will be essential to identify factors predicting response, and to understand how IGF-1R inhibition impacts on response to chemotherapy.
AVE1642 is a humanized version of murine monoclonal IGF-1R antibody EM164; both antibodies have been shown to induce regression of human tumor xenografts, inhibit metastasis, and enhance chemosensitivity [8] [9] [10] [11] . AVE1642 also enhances bortezomib-induced apoptosis in CD45 negative multiple myeloma cells [12] . In a phase I myeloma trial, AVE1642 was well tolerated but had insufficient activity to warrant further investigation, although myeloma cells were not screened for IGF-1R or CD45 [13] . The primary objective of this current study was to determine the safety of AVE1642 in patients with solid tumors. The first part of this phase I study had assessed escalating doses of AVE1642 alone or with 75 mg/ m 2 docetaxel. The maximal tolerated dose of AVE1642 was 12 mg/kg, and 6 mg/kg was selected for further study, based on AVE1642 pharmacokinetics (PK) and pharmacodynamic (PD) measures of IGF-I response. Tolerance of 6 mg/kg AVE1642 with 75 mg/m 2 docetaxel suggested the feasibility of further docetaxel escalation [14; Massard et al. submitted] . This second part of the phase I study tested the safety and feasibility of the selected dose of AVE1642 (6 mg/kg) in combination with four different anticancer regimens.
patients and methods trial design and objectives
This was an uncontrolled, four-arm multicenter study of IGF-1R antibody AVE1642 administered by an intravenous infusion in three weekly cycles with other anticancer therapies to patients with advanced solid tumors. On completion of chemotherapy, patients remained on AVE1642 until disease progression. The aim was to assess the feasibility of the treatment combinations, based on the incidence and severity of adverse events (AEs) and serious adverse events (SAEs) during the first cycle of treatment.
eligibility
To be eligible, patients were required to have pathologically confirmed advanced stage of solid tumor, one of the combination therapies should be a reasonable option given tumor characteristics and prior therapy, and provided no grade ≥3 toxic effects occurred during previous treatment with compounds in the same class. The specific inclusion criteria were age ≥18 years, Eastern Cooperative Oncology Group (ECOG) performance status 0-2, at least one measurable or evaluable lesion, and adequate hematologic, hepatic, and renal function (Hb ≥9 g/dl, neutrophils ≥1.5 × 10 9 /l, platelets ≥100 × 10 9 /l, creatinine <1.5× upper limit of normal (ULN) or calculated creatinine clearance ≥60 ml/min, bilirubin ≤ULN, AST/SGOT and ALT/ SGPT ≤2.5× ULN (≤5× ULN if liver metastases), and alkaline phosphatase ≤2.5× ULN (≤5× ULN if bone or liver metastases). Patients in the doxorubicin cohort were required to have left ventricular ejection fraction (LVEF) ≥50% within 1 month before the trial entry. Patients were excluded for brain metastases, peripheral neuropathy grade ≥2, pregnancy/lactation, HbA1c >8% within 2 months of inclusion, >2 prior lines of cytotoxic chemotherapy or >4 prior lines of therapy in total (including targeted agents) for advanced disease, known severe hypersensitivity to docetaxel or other drugs formulated in polysorbate 80, or any other contraindication to the selected combination therapy. The study was approved by the Research Ethics Committees and Institutional Review Boards of the participating centers. All participants gave written informed consent.
drug administration
All patients received 6 mg/kg AVE1642 by a slow intravenous infusion on day 1 of each 21-day cycle (q21), followed 30 min later by day 1 chemotherapy. The additional anticancer regimens are shown by cohort in Table 1 . Patients were enrolled in groups of three, with a 1-week interval between recruitment of the first three patients, and observation of the first group for 3 weeks before further enrollment. 
pharmacokinetic and pharmacodynamic monitoring
Patients underwent blood sampling for AVE1642 predose, during cycle 1 at intervals during the first 24 h, on days 3, 8, and 15, for subsequent cycles at day 22 before the next infusion, and 50-70 days after final study drug administration. Blood samples were collected for docetaxel, gemcitabine, erlotinib, and doxorubicin levels at cycle 1 predose, and at intervals during the first 48 h after the start of administration, with additional sampling for docetaxel PK for 6 h after administration of cycle 2. Blood for PD assessment was collected during cycle 1 at baseline; days 1, 2, 7, 14, and 21; at the end of each cycle for circulating IGF-I, IGF-II, and IGF-BP3; and human anti-humanized antibodies (HAHA). PK and PD parameters and AVE1642 HAHA were determined in serum or plasma using validated bioanalytical methods. AVE1642 was measured by enzyme immunoassay (EIA; lower limit of quantification, LLOQ: 2 μg/ml), and additional therapies by liquid chromatography/mass spectrometry (LC/MS-MS), with LLOQs of 1 ng/ml docetaxel, 0.1 ng/ml doxorubicin, 2 ng/ml erlotinib, 50 ng/ml gemcitabine. IGFs were measured by radioimmunoassay, with LLOQ for IGF-I of 16.7 ng/ml, and IGF-II 99.9 ng/ml. IGFBP3 was quantified by EIA (LLOQ 77.4 ng/ml) and HAHA by enzyme-linked immunosorbent assay. IGF levels were analyzed using GraphPad Prism version 5 (GraphPad, San Diego, CA).
results

patient characteristics
The characteristics of the 58 enrolled patients are shown in Table 1 . In total, 317 cycles of study treatment were administered, divided by cohort as shown in Table 2 . All patients were assessable for toxicity and PK/PD, and all but one for efficacy.
safety
All 58 patients had at least one AE attributed to trial treatment, the most common being diarrhea in 37/58 (64%), asthenia (34/ 58, 59%), nausea (30/58, 52%), and stomatitis (21/58, 36%). After documentation of grade 3 diarrhea in two patients in cohort C1, and febrile neutropenia in three patients in cohort D1, the protocol was amended, adding dose-reduced cohorts C2 and D2 (see Table 1 ). Grade 3 or 4 AEs were experienced by 36/58 patients (62%), including neutropenia in 16/58 (see Table 2 ), requiring treatment delay and/or dose-reduction in six patients. Grade 3 or 4 hyperglycemia occurred in 3/58 patients (5%), including two cases of grade 3 hyperglycemia in cohort B, and one grade 4 hyperglycemia in a cohort A patient with known type II diabetes, responding to insulin with normalization of blood glucose within 24 h. Dose delays were experienced by 23/58 (40%) patients, and 13/58 (22%) experienced DLTs of neutropenia, hyperglycemia, diarrhea, or stomatitis (Table 2 ). These results indicated that 6 mg/kg AVE1642 was tolerable in combination with 75 or 100 Sarcomas were all of soft tissue including four cases of leiomyosarcoma and one desmoplastic small round cell tumor. Number of prior regimens is shown as median (range), time from last prior treatment to first dose of study medication as median (range) in weeks. All patients received 6-mg/kg AVE1642 by a slow intravenous infusion on day 1 of each 21-day cycle, followed by day 1 chemotherapy: Doc, docetaxel; G, gemcitabine; E, erlotinib; Dox, doxorubicin. Chemotherapy was administered 30 min after completion of AVE1642 infusion: docetaxel by a 1-h intravenous infusion, gemcitabine by 30-min infusion, doxorubicin by intravenous injection, and erlotinib orally daily on an empty stomach. Prophylactic hematopoietic growth factors were not allowed during the first cycle of treatment. Thereafter, patients could receive G-CSF (Pegfilgrastim) for prophylaxis or treatment of neutropenia at the investigators' discretion.
original articles Annals of Oncology deteriorating cognitive function possibly related to study medication after 13 cycles of treatment. Forty SAEs occurred in 19 patients, of which 13 events were possibly related to AVE1642, and 3 patients experienced a SAE leading to death. These were the grade 4 hyperglycemia described above (cohort A), grade 3 oral stomatitis (cohort C2), and grade 3 febrile neutropenia (cohort D1). Fourteen additional patients died on study, all from disease progression.
pharmacokinetic analysis
In the previous dose-escalation study, AVE1642 exposure had been approximately dose-proportional between 3 and 24 mg/ kg, and clearance was similar (mean 363-477 ml/day) at all dose levels, suggesting attainment of a plateau of clearance from the lowest dose of 3 mg/kg [14; Massard et al. submitted].
In the current study, all patients received AVE1642 at 6 mg/kg. AVE1642 levels during cycle 1 showed a similar pattern across all cohorts, with the exception that levels were higher on days 7 and 14 in cohort C ( Figure 1A) , and AVE1642 clearance appeared greater in cohort D2 (Table 3) , for reasons that are currently unclear. Otherwise, there were no differences between cohorts in AVE1642 C max values, achieved 30-90 min after the start of AVE1642 infusion, final measured concentration (C last ), AVE1642 AUC, plasma terminal half-life (t½), and clearance (Table 3) . These data are comparable with PK parameters recorded for the 6 mg/kg cohort in the AVE1642 doseescalation phase (Massard et al. submitted). Comparison of PK data for the cytotoxic drugs (Table 3 ) with historical and inhouse data (not shown) indicated that there was no significant drug-drug interaction between AVE1642 and the cytotoxic drugs used in this study.
efficacy
Response data are summarized in Table 4 pharmacodynamic monitoring AVE1642 HAHAs were detected in one patient, only at the end of treatment. Plasma IGF-I, IGF-II, and IGF-BP3 levels are shown in Figure 2 . Circulating IGF-I and IGF-BP3 levels are regulated by the hypothalamic-pituitary axis [15] and are sensitive to blockade of pituitary IGF-1R. Pretreatment circulating IGF-I levels (34-374 ng/ml) were within the normal range, with no difference between patients achieving TTP ≥12 weeks (mean IGF-I 157.5 ng/ml, range 57-289 ng/nl), and those with TTP <12 weeks (169.6 ng/ml, range 33.8-374.0 ng/ ml). Circulating IGF-I rose approximately fourfold within 7 days of initiating treatment, with a subsequent plateau (Figure 2A ). Thus, in cohort A, baseline values were 151 ± 20 ng/ml, rising to 616 ± 65 ng/ml by day 21. Very similar increases were observed in cohorts B, C, and D (P < 0.001 for comparison of baseline versus peak cycle 1 value in each cohort), with no difference between cohorts. Circulating levels of the principal IGF-binding protein, IGF-BP3, showed approximately twofold treatment-related elevation, again without difference between cohorts ( Figure 2B ). These data are consistent with sustained IGF-1R blockade at least in the pituitary, compatible with effects of other IGF-1R antibodies [16] [17] [18] . Circulating IGF-II levels are higher than IGF-I and are only weakly regulated by the pituitary [15] . Study subjects had baseline IGF-II ranging from 323-945 ng/ml, with no difference between cohorts. We noted treatment-related IGF-II rise ( Figure 2C ): in cohort A, baseline IGF-II levels were 619.0 ± 33.32 ng/ml, rising by day 7-21 to 735.0 ± 36.67, with equivalent changes in cohorts B and D. The fold change was less marked (∼1.2-fold) than changes in IGF-I and IGF-BP3, but the differences between pretreatment and day 21 IGF-II levels were significant (P < 0.05) in all cohorts but C. By day 21 of cycle 1, IGF-II levels were significantly lower in cohort C (26) 9.57 ± 4.14 (43) Doc, docetaxel; G, gemcitabine; E, erlotinib; Dox, doxorubicin. PK data are provided as mean ± SD (CV%). C max , maximum observed concentration; C last , last measured concentration; AUC, area under the curve (for docetaxel, μg h/ml; for gemcitabine and doxorubicin, ng h/ml); t½, terminal half-life; Cl, clearance.
a Tabulated data are for docetaxel PK at cycle 1. N/A, not available. Analysis of cycle 2 data following 1-h infusion of docetaxel at 75 mg/m 2 showed mean ± SD docetaxel clearance of 26.4 ± 14.6 l/h/m² with AUC 3.67 ± 1.94 μg h/ml. Equivalent data for cycle 2 administration at 100 mg/m 2 showed docetaxel clearance of 28.9 ± 10.3 l/h/m² with AUC 3.87 ± 1.59 μg h/ml. There were no statistically significant differences in AVE1642 PK parameters between cohorts, or from PK parameters at 6 mg/kg in the dose-escalation phase (AUC 1030 ± 348 day μg/ml, plasma t½ 9.02 ± 1.89 days). Erlotinib PK parameters could not be determined due to erratic plasma profiles. original articles Annals of Oncology than in A, B, and D (P < 0.05 by ANOVA; Figure 2C ). Given that cohort C included two of the three patients achieving PR, and two achieving prolonged stabilization, we examined the relationship between IGF-II and response. Patients were divided into those achieving disease control (PR or stable disease of ≥12 weeks, 25 patients), and those on treatment for <12 weeks (32 patients). There was no difference in baseline IGF-II (596 ± 24 ng/ml in non/brief-responders versus 635 ± 22 ng/ml in the disease control group). On treatment IGF-II increased in patients discontinuing treatment <12 weeks, but not in those achieving prolonged disease control (mean values, respectively, 664 ± 25 versus 579 ± 24 ng/ml, P < 0.05). Comparing on treatment changes in these two groups, circulating IGF-II rose by 68 ± 25 ng/ml in non/briefresponders and fell by 55.5 ± 21 ng/ml in the disease control group (P < 0.001; Figure 2D ). The combination of AVE1642 with docetaxel caused no greater toxicity than was previously reported using 75 or 100 mg/m 2 docetaxel alone [19, 20] . AVE1642 was also tolerable with gemcitabine/erlotinib at the dose-reduced schedule administered in cohort C2. AVE1642 with 1250 mg/m 2 gemcitabine and 100 mg erlotinib caused dose-limiting diarrhea in 2/4 patients, compared with <10% reported previously on 100-150 mg erlotinib with gemcitabine [21, 22] . AVE1642 with 60 mg/m 2 doxorubicin induced neutropenia in 3/4 cases, compared with historical rates of ∼50% in patients treated with single-agent 60 mg/m 2 doxorubicin [23] . These data suggest that IGF-1R inhibition may exacerbate chemotherapy-induced toxicity, although numbers are small. In the absence of PK interaction, toxicity is unlikely be due to increased drug exposure, raising the prospect of pharmocodynamic interaction. Indeed, IGF-1R antibodies can induce myelotoxicity, more often thrombocytopenia than neutropenia [16, 17, 24] .
Hyperglycemia is a known class effect of IGF-1R inhibitors [1]. AVE1642 does not bind to the insulin receptor (IR), but EM164 was shown to downregulate IRs by binding to IGF-1R: IR hybrid receptors [25] , potentially impairing the function of variant IRs (IR-A) that contribute to tumor growth, and classical IRs (IR-B) that mediate glucose uptake [26] . In this study, significant hyperglycemia occurred only after steroid premedication for docetaxel dosing. Otherwise, the lack of serious hyperglycemia is consistent with data from trials of similar IGF-1R antibodies [17, 27, 28] , and with the doseescalation phase of this study, where grade 3 hyperglycemia occurred in 2/8 patients receiving 75 mg/m 2 docetaxel with AVE1642 at 18 mg/kg but not 6 mg/kg (Massard et al. submitted).
Responses occurred in three patients and durable stabilizations in 22, giving a disease control rate of 25/57 (44%). Responding patients included one with metastatic melanoma treated with docetaxel and two patients with leiomyosarcoma on the erlotinib/gemcitabine arm. Both cytotoxic drugs have reported single-agent activity in these tumor types: docetaxel of 17% (5/30) in melanoma [29] , and gemcitabine of 7% (1/14) in previously treated leiomyosarcoma [30] . Prior studies have noted the activity of IGF-1R antibody in sarcomas [17, 24, 31] , and the utility of IGF-1R antibody with gemcitabine in pancreatic cancer [5] . IGF-1R inhibition may enhance chemosensitivity via regulation of apoptosis and DNA repair [32] [33] [34] [35] , but there is potential for antagonism if cell cycle arrest protects from phase-specific cytotoxic drugs, possibly explaining the adverse outcome when IGF-1R antibody was added to irinotecan in patients with colorectal cancer [6] . Therefore, scheduling is an important issue when combining targeted agents with chemotherapy, with evidence of more effective chemosensitization when administering IGF-1R therapeutics after the cytotoxic drug [36] , rather than before, as in this study.
Dramatic and durable responses have been noted in this and other studies of IGF-1R therapeutics [2, 5, 17] , but as yet there is no clear biomarker for sensitivity [7] . High pretreatment levels of free or total IGF-I appear to correlate with response to IGF-1R antibodies figitumumab and R1507 [24, [37] [38] [39] [40] . In the current study, free IGF-I was not measured, and there was no association between baseline total IGF-I and response. There was, however, evidence that on treatment IGF-II increased in non/brief-responders, and fell in patients achieving durable disease control. At present, it is not clear whether these differences are biologically significant; it is plausible that rising IGF-II could mediate AVE1642 resistance by activating IR-A, as was recently shown for IGF-1R antibody SCH717454 in sarcoma models [41] .
In summary, 6 mg/kg AVE1642 was tolerable in combination with 75-100 mg/m 2 docetaxel and with 1000 mg/ m 2 gemicibine and 75 mg erlotinib, but not with 1250 mg/m 2 gemicibine and 100 mg erlotinib due to gastrointestinal toxicity, or 60 mg/m 2 doxorubicin due to myelotoxicity. Of 57 patients assessable for response, 25 (44%) achieved durable disease control, and we identified an association between on treatment IGF-II and disease response. Issues of scheduling and identification of predictive biomarkers remain to be resolved.
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